Abstract
BACKGROUND
The current study was designed to evaluate the efficacy and toxicity of the continuous oral administration of a combination of cyclophosphamide (50 mg/day given in the morning) and dexamethasone (1 mg/day given in the evening) in patients with prostate specific antigen (PSA) progression despite single or multiagent hormone therapy and antiandrogen withdrawal.
METHODS
The authors retrospectively evaluated the medical records of all patients with prostate carcinoma who were treated with dexamethasone and cyclophosphamide and who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.
RESULTS
Using clinical response guidelines set forth by the Prostate Specific Antigen Working Group, 29% of patients were found to have a โฅ 80% reduction in PSA, 39% were found to have a 50โ79% reduction in PSA, 6% were found to have a < 50% decrease in PSA, and 26% experienced disease progression while receiving treatment. The duration of response was 8 months (95% confidence interval [95% CI], 4โ10 months). The duration of treatment was 9 months (95% CI, 6โ14 months). The treatment was reported to be well tolerated with side effects being primarily bruising, Cushingoid facies, and gastrointestinal distress.
CONCLUSIONS
In the current study, lowโdose dexamethasone and cyclophosphamide demonstrated efficacy as salvage therapy in the treatment of patients with hormoneโrefractory prostate carcinoma. Cancer 2003. ยฉ 2003 American Cancer Society.
DOI 10.1002/cncr.11713